Belvedere Trading
FENC icon

Belvedere Trading’s Fennec Pharmaceuticals FENC Stock Holding History

Belvedere Trading’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,790
Closed -$155K – 502
2021
Q3 		$155K Buy
+17,790
New +$133K ﹤0.01% 285

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Belvedere Trading's FENC Position: Q4 2021 in Review

Belvedere Trading sold out of Fennec Pharmaceuticals (FENC) in Q4 2021, closing a stake of 17,790 shares — an estimated $155K sold.

Belvedere Trading first reported a position in FENC in Q3 2021 and held it in 1 quarter. The position peaked at $155K in Q3 2021. 30 funds tracked by Wall St. Rank hold FENC as of Q4 2021.

  • Belvedere Trading reported no remaining Fennec Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Belvedere Trading sold 17,790 Fennec Pharmaceuticals shares in Q4 2021, an estimated $155K.
  • Belvedere Trading first reported a position in Fennec Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Belvedere Trading's Fennec Pharmaceuticals position peaked at $155K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.